World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
83
Citations
38472
World Ranking
15380
National Ranking
7755

Overview

Michael W. Fried is affiliated with the University of North Carolina at Chapel Hill in the United States. Their research primarily focuses on medicine, with a specialization in hepatology, epidemiology, and infectious diseases, alongside contributions to oncology and rheumatology.

Their recent notable publications include:

  • Patient Characteristics and Outcomes of 11 721 Patients With Coronavirus Disease 2019 (COVID-19) Hospitalized Across the United States, 2020, Clinical Infectious Diseases
  • DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort, 2020, Journal of Hepatology
  • Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review, 2020, UNC Libraries
  • Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy, 2020, Hepatology
  • Prevalence and incidence of iron deficiency in European community-dwelling older adults: an observational analysis of the DO-HEALTH trial, 2022, Aging Clinical and Experimental Research

Frequent co-authors who have collaborated extensively with Michael W. Fried include:

  • K. Rajender Reddy
  • Adrian M. Di Bisceglie
  • Andrea R. Mospan
  • Norah A. Terrault
  • Anna S. Lok

Michael W. Fried's work has been published often in the following venues:

  • UNC Libraries
  • Journal of Hepatology
  • Schweizer Gastroenterologie
  • Alimentary Pharmacology & Therapeutics
  • Hepatology

The major subfields of study covered by Michael W. Fried include:

  • Hepatology
  • Epidemiology
  • Infectious Diseases
  • Oncology
  • Rheumatology

Main research topics explored in their body of work consist of:

  • Hepatitis C virus research
  • Liver Disease Diagnosis and Treatment
  • Hepatitis B Virus Studies
  • Liver Disease and Transplantation
  • Systemic Lupus Erythematosus Research
  • HIV/AIDS drug development and treatment
  • Liver Diseases and Immunity

Best Publications

  • Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

    Michael W. Fried;Mitchell L. Shiffman;K. Rajender Reddy;Coleman Smith

  • Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B

    George K.K. Lau;Teerha Piratvisuth;Kang Xian Luo;Patrick Marcellin

  • Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

    Kris V. Kowdley;Stuart C. Gordon;K. Rajender Reddy;Lorenzo Rossaro

  • A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness

    Lieven Stuyver;Sija De Gendt;Caroline Van Geyt;Fabien Zoulim

  • Response-guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

    Kenneth K.E. Sherman;Steven S.L. Flamm;Nezam N.H. Afdhal;David Nelson

  • Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis

    M. P. Curry;J. G. O'Leary;N. Bzowej;A. J. Muir

  • Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

    Michael Charlton;Gregory T. Everson;Steven L. Flamm;Princy Kumar

  • Hepatic failure and lactic acidosis due to fialuridine (fiau), an investigational nucleoside analogue for chronic hepatitis b

    Robin Mckenzie;Michael W. Fried;Richard Sallie;Hari Conjeevaram

  • Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review

    Oluwaseun Falade-Nwulia;Catalina Suarez-Cuervo;David R. Nelson;Michael W. Fried

  • Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

    Peter Ferenci;Michael W. Fried;Mitchell L. Shiffman;Coleman I. Smith

  • Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

    Hari S. Conjeevaram;Michael W. Fried;Lennox J. Jeffers;Norah A. Terrault

  • Liver transplantation for acute liver failure from drug induced liver injury in the United States

    Mark W. Russo;Joseph A. Galanko;Roshan Shrestha;Michael W. Fried

  • Efficacy and safety of pegylated (40-kd) interferon α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis C☆

    K. Rajender Reddy;Teresa L. Wright;Paul J. Pockros;Mitchell Shiffman

  • Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study

    ME Eyster;MW Fried;AM Di Bisceglie;JJ Goedert

  • Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

    A. M. Di Bisceglie;H. S. Conjeevaram;M. W. Fried;R. Sallie

  • Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

    Ira M Jacobson;Gregory J Dore;Graham R Foster;Michael W Fried

  • A pilot study of ribavirin therapy for chronic hepatitis C.

    Adrian M. di Bisceglie;Michiko Shindo;Tse-Ling Fong;Michael W. Fried

  • Side effects of therapy for chronic hepatitis C.

    Mark W. Russo;Michael W. Fried

  • Once-Daily Simeprevir (TMC435) With Pegylated Interferon and Ribavirin in Treatment-Naïve Genotype 1 Hepatitis C: The Randomized PILLAR Study

    Michael W. Fried;Maria Buti;Gregory J. Dore;Robert Flisiak

  • Safety and efficacy of sofosbuvir‐containing regimens in hepatitis C‐infected patients with impaired renal function

    Varun Saxena;Farrukh M. Koraishy;Meghan E. Sise;Joseph K. Lim

Frequent Co-Authors

David R. Nelson
David R. Nelson University of Tennessee Health Science Center
K. Rajender Reddy
K. Rajender Reddy University of Pennsylvania
Adrian M. Di Bisceglie
Adrian M. Di Bisceglie Saint Louis University
Norah A. Terrault
Norah A. Terrault University of Southern California
Mark S. Sulkowski
Mark S. Sulkowski Johns Hopkins University School of Medicine
Stefan Zeuzem
Stefan Zeuzem Goethe University Frankfurt
Richard K. Sterling
Richard K. Sterling Virginia Commonwealth University
Nezam H. Afdhal
Nezam H. Afdhal Beth Israel Deaconess Medical Center
Andrew J. Muir
Andrew J. Muir Duke University
Ira M. Jacobson
Ira M. Jacobson New York University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The medical field offers a wide array of online degrees and alternative pathways for students seeking flexible study options. For those interested in preventative health and nutrition, a best online food science degree can open doors to roles in research, dietary consulting, and public health education.

For students who aspire to leadership positions in healthcare administration, there are reputable online mha programs cahme accredited. These programs emphasize high standards in management and prepare graduates for executive roles across hospitals and healthcare systems.

If you’re a registered nurse seeking advancement without excessive time in clinical settings, several rn to bsn programs without clinicals allow you to complete your BSN online with more flexibility. These options are ideal for working nurses balancing professional and personal responsibilities.

For those ready for the highest level of nursing practice, accelerated options like a 1 year dnp program online offer an efficient pathway to advanced clinical and leadership roles.

Best Scientists Citing Michael W. Fried

Trending Scientists